Effectiveness of Microdosed GLP-1 in Improving Health, Quality of Life, and Longevity Measures

Part of paid clinical trials in Ann Arbor, Michigan.

Sponsor
AgelessRx
Study ID
NCT07092605
Phase
EARLY_PHASE1
Status
Enrolling By Invitation

Conditions

  • Alertness
  • Immune Health
  • Inflammation
  • Longevity
  • Mood
  • Pain Management
  • Quality of Life
  • Weight Management

Eligibility Criteria

Sex
ALL
Age
18 Years - 65 Years
Healthy Volunteers
Accepted

Interventions

  • GLP-1 — DRUG
    Sublingual GLP1 (weekly), Subcutaneous GLP1 (weekly), Sublingual Placebo (weekly) for up to 6 months.
  • Placebo — DRUG
    Sublingual Placebo (weekly) for up to 6 months

Study Details

The goal of this clinical study has two objectives. The Primary Objective is to evaluate the effectiveness of microdosed GLP-1 receptor agonists in improving measures of health, quality of life, and longevity. The Secondary Objective: To assess the impact of these therapies on weight management practices and metabolic health.

Key Dates

Start date
Nov 1, 2024
Status verified
Jun 2025
Primary completion
Nov 1, 2025
Completion
Dec 1, 2025

Study Design

Enrollment
150 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Placebo Comparator: Oral Placebo
    Placebo administered in PCCA sub-magna compounding base only.
  • Active Comparator: Sublingual GLP1
    Semaglutide 1mg/1ml administered in PCCA sub-magna compounding base only.
  • Active Comparator: Subcutaneous GLP1
    Semaglutide 1mg/ml x5ml

Primary Outcome Measure

Change in self-reported pain levels in participants microdosing GLP1s [ Time Frame: 6 months ]

Locations (1)

FacilityCityStateZIPSite coordinators
AgelessRxAnn ArborMichigan48104-

Find similar trials in Ann Arbor, MI

By research site
AgelessRx· Ann Arbor, MI

Related Studies